I also hold the MHRA responsible for the slow pace of this process. GBM is one of the deadliest cancers and absolutely warrants a priority review, so it’s hard to understand why it’s taking them so long to make a decision. The compassionate use program has been in place long enough to show its impact on patients. It's incredibly frustrating, and our initial excitement has completely faded due to their sluggishness. Every day feels like nothing has moved forward....
we wake up, check for updates, only to find more debates and discussions over old filings like the 8K or 10-Q. It’s been nearly 13 months since the company submitted, and the process is beyond exhausting.
Market Data 
Markets 
